Table 2 Epigenetic drugs in clinical trials
Class | Drug | Treatment method | Cancer type | Current status | Clinical trial | Reference/identifier |
|---|---|---|---|---|---|---|
DNMTi | Azacitidine | Only | MDS, CMML | Completed | FDA approved | [279] |
Only | AML | Completed | Phase III | NCT01074047 | ||
+ Pembrolizumab | Pancreas cancer | Recruiting | Phase II | NCT03264404 | ||
+ Valproic acid | Advanced cancer | Completed | Phase I | NCT00496444 | ||
+ Quizartinib | Recurrent AML, CMML and MDS | Active, not recruiting | Phase I/ II | NCT01892371 | ||
Decitabine | Only | MDS, CMML | Completed | FDA approved | [280] | |
Only | AML | Completed | Phase III | NCT00260832 | ||
+ Fludarabine and busulfan | AML, MDS | Completed | Phase 1 | NCT01455506 | ||
+ Quizartinib + venetoclax | Recurrent AML and MDS | Recruiting | Phase I/ II | NCT03661307 | ||
Guadecitabine | Only | AML | Completed | Phase 2 | NCT01261312 | |
Only | HCC | Completed | Phase 2 | NCT01752933 | ||
+ Pembrolizumab + mocetinostat | Lung cancer | Recruiting | Phase 1 | NCT03220477 | ||
Disulfiram | Only | Metastatic breast cancer | Recruiting | Phase II | NCT03323346 | |
Only | Prostat cancer | Completed | Not applicable | NCT01118741 | ||
HDACi | Romidepsin | Only | CTCL | Completed | FDA approved | [281] |
+ Erlotinib | Stage III/ IV NSCLC | Completed | Phase I | NCT01302808 | ||
HDACi | Panobinostat (LBH-589) | + Bortezomib and dexamethasone | Myeloma who received at least bortezomib and IMiDs | Completed | FDA approved | [282] |
Only | Prostat cancer | Completed | Phase I | NCT00663832 | ||
Only | Colorectal cancer | Completed | Phase II | NCT00690677 | ||
Vorinostat (SAHA) | Only | CTCL | Completed | FDA approved | [283] | |
Only | AML | Completed | Phase 2 trial | NCT00305773 | ||
+ Radiation therapy | AML Pancreatic cancer | Terminated | Phase I/II | NCT00831493 | ||
+ Carboplatin + etoposide | SCLC | Terminated | Phase I/II | NCT00702962 | ||
Only | NSCLC | Completed | Phase I | NCT01059552 | ||
Only | Glioblastoma stem cells | Completed | Phase II | [284] | ||
Chidamide | Only | PTCL | Completed | FDA approved | [285] | |
+ Exemestane + placebo | Breast cancer | Active, not recruiting | Phase III | NCT02482753 | ||
+ Paclitaxel + carboplatin + placebo | NSCLC | Completed | Phase II | NCT01836679 | ||
Givinostat (ITF2357) | Only | Lung CSCs | Completed | Phase II | [284] | |
Only | Chronic myeloproliferative neoplasms | Active, not recruiting | Phase II | NCT01761968 | ||
Belinostat | Only | PTCL | Completed | FDA approved | [286] | |
Only | Advanced cancer | Completed | Phase I | NCT01583777 | ||
+ Ribociclib | Metastatic breast cancer, recurrent ovarian carcinoma | Recruiting | Phase I | NCT04315233 | ||
HDMi | Tranylcypromine | + Tretinoin | AML, MDS, Leukemia | Completed | Phase I | NCT02273102 |
+ All-trans retinoic acid + cytarabin | AML, MDS | Recruiting | Phase I/ II | NCT02717884 | ||
Tazemetostat | Only | Malignant mesothelioma | Completed | Phase II | NCT02860286 | |
Only | Rhabdoid tumors, NI1-negative tumors, synovial sarcoma malignant, rhabdoid tumors of ovary | Recruiting | Phase I | NCT02601937 | ||
CPI-1205 | + Ipilimumab | Advansed solid tumors | Completed | Phase I | NCT03525795 | |
Only | B cell lymphoma | Completed | Phase I | NCT02395601 | ||
ncRNA | EnGeneIC (mir-16 mimic) | Mitoxantrone packaged EDV (EnGeneIC delivery vehicle) | Solid tumors, CNS tumors | Recruiting | Phase I | NCT02687386 |
MRX34 (mir-34a mimic) | Only | Primary liver cancer, SCLC, NSCLC, lymphoma, melanoma | Terminated | Phase I | NCT01829971 | |
TargomiRs | Only | MPM, NSCLC | Completed | Phase I | NCT02369198 | |
Patisiran | Only | hereditary transthyretin amyloidosis | Completed | FDA approved | [287] | |
Cobomarsen (anti-mir155) | Only | CTCL, CLL, ATLL | Completed | Phase I | NCT02580552 | |
+ Vorinostat | Cutaneous T cell lymphoma/mycosis fungoides | Terminated | Phase II | NCT03713320 |